title: Sentinel lymph node biopsy after percutaneous diagnosis of nonpalpable breast cancer.
abstract: OBJECTIVE
  To determine the technical success rate of sentinel lymph node biopsy in women with nonpalpable infiltrating breast cancer diagnosed by using percutaneous core biopsy and to determine the frequency with which sentinel lymph node biopsy obviated axillary dissection.
  
  
  METHODS
  Retrospective review revealed 33 women who underwent sentinel node biopsy after percutaneous core biopsy diagnosis of nonpalpable infiltrating breast cancer. Sentinel nodes were identified with radioisotope and blue dye; the procedure was technically successful if sentinel nodes were found at surgery. All sentinel nodes were excised. Axillary dissection was performed if tumor was present in sentinel nodes.
  
  
  RESULTS
  Sentinel nodes were found at surgery in 30 women (91%). Sentinel nodes were identified with both radioisotope and blue dye in 22 (73%) of these women, with only radioisotope in six (20%), and with only blue dye in two (7%). Sentinel nodes were found in 12 (80%) of 15 women in the first half of the study versus all 18 (100%) women in the second half (P = .08). Sentinel nodes were free of tumor in 23 (77%) of 30 women. In six (86%) of seven women with tumor in sentinel nodes, the sentinel nodes were the only nodes with tumor.
  
  
  CONCLUSIONS
  Sentinel node biopsy was successful in 30 women (91%) with nonpalpable infiltrating carcinoma diagnosed with percutaneous core biopsy and obviated axillary dissection in 23 women (70%). Using both radioisotope and blue dye may increase the success rate. A learning curve exists, and success improves with experience.
authors.affiliation: Breast Imaging Section, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
authors.forename: L
authors.initials: L
authors.lastname: Liberman
authors.forename: H S
authors.initials: HS
authors.lastname: Cody
authors.forename: A D
authors.initials: AD
authors.lastname: Hill
authors.forename: P P
authors.initials: PP
authors.lastname: Rosen
authors.forename: S D
authors.initials: SD
authors.lastname: Yeh
authors.forename: T
authors.initials: T
authors.lastname: Akhurst
authors.forename: E A
authors.initials: EA
authors.lastname: Morris
authors.forename: A F
authors.initials: AF
authors.lastname: Abramson
authors.forename: P I
authors.initials: PI
authors.lastname: Borgen
authors.forename: D D
authors.initials: DD
authors.lastname: Dershaw
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001706:Biopsy; D001707:Biopsy, Needle; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000473:pathology; D004396:Coloring Agents; D005260:Female; D006801:Humans; D008197:Lymph Node Excision; D008198:Lymph Nodes / Q000000981:diagnostic imaging / Q000473:pathology*; D008207:Lymphatic Metastasis; D008875:Middle Aged; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000008:administration & dosage; D012189:Retrospective Studies; D013671:Technetium Tc 99m Sulfur Colloid / Q000008:administration & dosage
chemical_list: D004396:Coloring Agents; D019275:Radiopharmaceuticals; D013671:Technetium Tc 99m Sulfur Colloid